| EMA number | EMEA/H/C/001015 |
| ATC code | J07BB02 |
| Authorisation | 26 September 2008 |
| Withdrawn | 3 November 2011 |
| Revision | 3 |
Active immunisation against H5N1 subtype of Influenza A virus. This indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared from A/VietNam/1194/2004 NIBRG-14 (H5N1) (see section 5.1). Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals 3.75 µg should be used in accordance with official guidance.